ERBB2 and gastric cancer: A phase I study included patients with locally advanced and metastatic HER2-positive GC, breast, and gastroesophageal cancers that could not be removed by surgery and receiving a combination of MK-2206, lapatinib ditosylate, and trastuzumab.